LG AI Research Institute has released a new model of Exemplary Pass, a precision medical artificial intelligence (AI) model.

On the 9th, LG AI Research Institute unveiled ‘EXAONE Path 2.0’, a next-generation precision medical AI model.

Bio is one of the ABCs (AI, Bio, and Clean Tech) that LG Group Chairman Koo Kwang-mo cited as a future growth engine. Exempathy 2.0 is expected to play an important role in the group’s growth strategy.

Exempathy 2.0 is an upgrade of the 1.0 model released in January last year and the 1.5 model released last month, and has learned much higher quality data than the existing model. Pathologic tissue images (WSI) can precisely analyze and predict genetic variation and expression form, microscopic changes in human cells and tissues, and structural features.

Exemplary Pass 2.0 learned multiomics information such as DNA and RNA containing WSI and genetic information together. WSI is a high-resolution digital image taken during the pathologic diagnosis process of observing a patient’s tissue sample under a microscope. However, if AI simply analyzes this, there is a high possibility that a “characteristic collapse phenomenon” will occur, which will lead to poor prediction accuracy.

Exemplary Pass 2.0 applied a new technology that learns from small units to WSI, increasing the accuracy of predicting genetic mutations to 78.4%, the world’s highest level.

In addition, gene activity can be predicted only by image analysis without expensive dielectric tests.

Park Yong-min, leader of the AI business team at LG AI Research Institute, said, “If Exemplar Pass 2.0 is used, the genetic test time that took more than two weeks can be shortened to less than a minute, helping to secure golden time for treatment of cancer patients. If doctors and pharmaceutical companies use Exemplar Pass 2.0, they can identify target treatments in a short time.” The LG AI Research Institute also released additional models specializing in specific diseases such as lung and colon cancer.

LG AI Research Institute also announced a plan to cooperate with Vanderbilt University Medical Center in the United States. It is joined by a research team led by Korean scholar Hwang Tae-hyun, who leads the stomach cancer project of Cancer Moonshot, a cancer conquest project led by the U.S. government. Professor Hwang said, “Our goal is to create an AI platform that can help medical staff treat and treat patients in the actual medical field. The AI platform will not be just a diagnostic tool, but a game changer that innovates the entire process of new drug development.”

Starting with the field of cancer, LG AI Research Institute and Professor Hwang’s research team plan to expand the scope of research to rejection of transplants, immunology, and diabetes in the future. LG AI Research Institute is planning to introduce Exemite Pass 2.0 at the ‘LG AI Talk Concert 2025’ on the 22nd.

[Reporter Lee Deok-ju]